RSS Content

Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On August 9, 2017

BOULDER, Colo., Aug. 3, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the fourth quarter and full year of fiscal 2017 and hold a conference call to discuss those results on Wednesday, August 9, 2017.  Ron Squarer, Chief Executive Officer, will lead the call.

Date:

Wednesday, August 9, 2017

Time:

9:00 a.m. Eastern Time

Toll-Free:

(844) 464-3927

Toll:

(765) 507-2598

Pass Code:

44703107

Array BioPharma. (PRNewsFoto/Array BioPharma Inc.) (PRNewsFoto/)

Webcast, including Replay and Conference Call Slides:
http://edge.media-server.com/m/p/af6yqtav

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

CONTACT:

Tricia Haugeto                          


Array BioPharma Inc.


(303) 386-1193


thaugeto@arraybiopharma.com

 

 

View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-2017-on-august-9-2017-300499225.html

SOURCE Array BioPharma